Birchview Capital’s Amicus Therapeutics FOLD Stock Holding History

Birchview Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-253,000	Closed	-$3.6M	–	75
2025 Q4	$3.6M	Hold	253,000	–	–	2.11%	14
2025 Q3	$1.99M	Buy	253,000 +225,000	+804%	+$1.6M	1.51%	18
2025 Q2	$160K	Hold	28,000	–	–	0.16%	61
2025 Q1	$228K	Hold	28,000	–	–	0.2%	50
2024 Q4	$264K	Hold	28,000	–	–	0.21%	52
2024 Q3	$299K	Hold	28,000	–	–	0.26%	47
2024 Q2	$278K	Hold	28,000	–	–	0.26%	45
2024 Q1	$330K	Hold	28,000	–	–	0.27%	43
2023 Q4	$397K	Hold	28,000	–	–	0.31%	38
2023 Q3	$340K	Hold	28,000	–	–	0.29%	38
2023 Q2	$352K	Hold	28,000	–	–	0.26%	44
2023 Q1	$311K	Hold	28,000	–	–	0.24%	43
2022 Q4	$342K	Sell	28,000 -10,000	-26%	-$113K	0.24%	40
2022 Q3	$397K	Hold	38,000	–	–	0.28%	43
2022 Q2	$408K	Hold	38,000	–	–	0.3%	40
2022 Q1	$360K	Hold	38,000	–	–	0.26%	46
2021 Q4	$439K	Hold	38,000	–	–	0.28%	47
2021 Q3	$363K	Hold	38,000	–	–	0.25%	49
2021 Q2	$366K	Hold	38,000	–	–	0.22%	52
2021 Q1	$375K	Hold	38,000	–	–	0.22%	45
2020 Q4	$877K	Hold	38,000	–	–	0.51%	30
2020 Q3	$537K	Hold	38,000	–	–	0.36%	30
2020 Q2	$573K	Hold	38,000	–	–	0.35%	33
2020 Q1	$351K	Hold	38,000	–	–	0.31%	34
2019 Q4	$370K	Hold	38,000	–	–	0.27%	40
2019 Q3	$305K	Hold	38,000	–	–	0.2%	37
2019 Q2	$474K	Hold	38,000	–	–	0.29%	34
2019 Q1	$517K	Hold	38,000	–	–	0.32%	29
2018 Q4	$364K	Hold	38,000	–	–	0.34%	32
2018 Q3	$459K	Buy	38,000 +4,000	+12%	+$55.9K	0.3%	38
2018 Q2	$531K	Hold	34,000	–	–	0.36%	30
2018 Q1	$511K	Buy	34,000 +24,000	+240%	+$365K	0.34%	30
2017 Q4	$144K	Hold	10,000	–	–	0.08%	37
2017 Q3	$151K	Buy	+10,000	New	+$132K	0.08%	36

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Birchview Capital's FOLD Position: Q1 2026 in Review

Birchview Capital sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 253,000 shares — an estimated $3.6M sold.

Birchview Capital first reported a position in FOLD in Q3 2017 and held it in 34 quarters. The position peaked at $3.6M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Birchview Capital reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Birchview Capital sold 253,000 Amicus Therapeutics shares in Q1 2026, an estimated $3.6M.
Birchview Capital first reported a position in Amicus Therapeutics in Q3 2017 and held it in 34 quarters.
Birchview Capital's Amicus Therapeutics position peaked at $3.6M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.